Spruce Biosciences, Inc. (SPRB)
NASDAQ: SPRB · Real-Time Price · USD
43.31
+0.42 (0.98%)
At close: Nov 13, 2026, 4:00 PM EST
43.12
-0.19 (-0.44%)
After-hours: Nov 13, 2026, 7:30 PM EST
Spruce Biosciences Employees
Spruce Biosciences had 25 employees as of September 30, 2026. The number of employees increased by 16 or 177.78% compared to the same quarter last year. That makes Spruce Biosciences the 37,861st largest employer in the world and 5,359th in the United States.
Employees
25
Change (1Y)
16
Growth (1Y)
177.78%
Revenue / Employee
n/a
Profits / Employee
-$2,685,880
Market Cap
124.47M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Sep 30, 2026 | 25 | 16 | 177.78% |
| Jun 30, 2026 | 22 | 13 | 144.44% |
| Mar 31, 2026 | 14 | -6 | -30.00% |
| Dec 31, 2025 | 8 | -13 | -61.90% |
| Sep 30, 2025 | 9 | -13 | -59.09% |
| Jun 30, 2025 | 9 | -13 | -59.09% |
| Mar 31, 2025 | 20 | -2 | -9.09% |
| Dec 31, 2024 | 21 | -8 | -27.59% |
| Sep 30, 2024 | 22 | -9 | -29.03% |
| Jun 30, 2024 | 22 | -10 | -31.25% |
| Mar 31, 2024 | 22 | -8 | -26.67% |
| Dec 31, 2023 | 29 | 2 | 7.41% |
| Sep 30, 2023 | 31 | 9 | 40.91% |
| Jun 30, 2023 | 32 | 15 | 88.24% |
| Mar 31, 2023 | 30 | 14 | 87.50% |
| Dec 31, 2022 | 27 | 12 | 80.00% |
| Sep 30, 2022 | 22 | 3 | 15.79% |
| Jun 30, 2022 | 17 | -4 | -19.05% |
| Mar 31, 2022 | 16 | -3 | -15.79% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Abeona Therapeutics | 226 |
| Codexis | 146 |
| Molecular Partners AG | 134 |
| Adagene | 128 |
| Foghorn Therapeutics | 106 |
| PolyPid | 75 |
| OnKure Therapeutics | 45 |
| Zura Bio | 40 |
SPRB News
- 5 days ago - Spruce Biosciences Transcript: 3rd Annual Guggenheim Healthcare Innovation Conference - Transcripts
- 6 days ago - Spruce Biosciences reports Q3 EPS ($8.51), consensus ($5.51) - TheFly
- 6 days ago - Spruce Biosciences sees cash runway into 2H27 - TheFly
- 6 days ago - Spruce Biosciences Reports Third Quarter 2026 Financial Results and Provides Corporate Updates - Business Wire
- 6 days ago - Spruce Biosciences Earnings release: Q3 2026 - Filings
- 6 days ago - Spruce Biosciences Quarterly report: Q3 2026 - Filings
- 6 days ago - Spruce Biosciences separates CRHX-101 program into Adrenyx Biosciences - TheFly
- 6 days ago - Spruce Biosciences Announces Separation of CRHX-101 (Formerly SPR-202) Program into Adrenyx Biosciences - Business Wire